Henlius Biotech has embarked on a significant strategic partnership with Sandoz, granting the latter exclusive commercialization rights outside of China for a range of monoclonal antibodies and antibody-drug conjugate (ADC) biosimilars. The collaboration, valued at up to $322 million, marks an important advancement in the companies’ ongoing relationship.
Expanding the Partnership
This collaboration builds upon a foundation established in April 2025 when Henlius and Sandoz entered into an exclusive commercialization agreement for HLX13, Henlius’ proposed biosimilar of ipilimumab. This earlier arrangement covered 46 countries, including major markets like Europe and the United States. The new agreement not only deepens their previous work in oncology biosimilars but also broadens the scope to encompass multiple products, setting the stage for a comprehensive multi-product strategy.
Under the terms of this new collaboration, Sandoz will receive exclusive rights for the registration and commercialization of up to ten partnered products worldwide, excluding China. Many of these products are currently in the early stages of development, necessitating collaboration from the outset of each project. The partnership encompasses the entire product lifecycle, which includes development, regulatory submissions, manufacturing, launch, commercialization, and ongoing lifecycle management.
Financial Framework of the Collaboration
The financial structure of the deal includes an upfront payment, milestone payments, and a non-refundable option fee, culminating in a total potential value of $322 million. For the year 2026 alone, Henlius anticipates receiving up to $100.5 million from this collaboration.
Henlius will leverage its integrated biologics platform for the development, manufacturing, and supply of the partnered products. This platform is designed to expedite the transition of early-stage molecules into viable therapies. Sandoz, with its extensive experience marketing approximately 1,300 medicines across 100 countries and impacting over a billion patients globally, will contribute its expertise in registration, market access, launch, and commercialization. The collaboration aims to integrate Sandoz’s insights into global market strategies early in the development process, enhancing execution efficiency.
Initial Assets and Their Potential
The initial phase of the collaboration includes three key assets: HLX05-N, a proposed biosimilar for cetuximab; HLX16, a proposed biosimilar for evolocumab; and a biosimilar for belimumab. Additionally, Sandoz has secured an option for HLXTE-HAase1001, a recombinant human hyaluronidase.
The territory for HLX05-N encompasses the United States, Canada, the European Union, and several other European nations, as well as Japan, Australia, and New Zealand. There are also semi-exclusive rights in select Asian markets. In contrast, HLX16 and the proposed belimumab biosimilar will have exclusive global rights outside of China.
Pipeline Assets: Current Status
HLX05-N is being developed to target metastatic colorectal cancer and head and neck squamous cell carcinoma. In July 2026, the first patient was dosed in a Phase I clinical study in China. HLX16 is aimed at treating primary hypercholesterolemia and is currently in preclinical research stages. The belimumab biosimilar seeks to address systemic lupus erythematosus and lupus nephritis and is also in preclinical development. Moreover, HLXTE-HAase1001 aims to streamline treatment by converting lengthy intravenous infusions into rapid subcutaneous injections, thereby enhancing patient experience.
A Strategic Move for Global Expansion
This collaboration represents a pivotal element of Henlius’ globalization strategy, showcasing its strengths in biologics research and development, quality assurance, international registration, large-scale manufacturing, and global supply chains. The partnership further validates the global potential of Henlius’ biosimilars platform, positioning the company for significant growth in international markets.
Conclusion
The $322 million collaboration between Henlius and Sandoz is a strategic opportunity for both companies to expand their reach and enhance their product offerings. By combining Henlius’ innovative development capabilities with Sandoz’s global commercialization expertise, this partnership is poised to make a substantial impact in the biopharmaceutical landscape.
Key Takeaways:
- Henlius and Sandoz’s partnership is valued at up to $322 million.
- The agreement includes commercialization rights for ten monoclonal antibodies and ADC biosimilars outside of China.
- Initial assets include HLX05-N, HLX16, and a belimumab biosimilar, with plans for further development.
- The collaboration seeks to integrate market insights early in the development process for efficient execution.
- This deal is a crucial part of Henlius’ strategy to enhance its global presence in the biopharmaceutical market.
Read more → www.pharmexec.com